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Abstract
Lysyl oxidase-like 2 (LOXL2) is a copper-dependent monoamine oxidase that contributes to
the remodelling of the extracellular matrix (ECM) by cross linkage of collagen and elastin
fibres and has emerged as a potential therapeutic target in cancer and fibrosis. In the skin,
LOXL2 is essential for epidermal cell polarity and differentiation. However, its role in the der-
mis has not been evaluated. We found that Loxl2 is dispensable for mouse dermal develop-
ment, maturation and homeostasis, yet affects dermal stiffness. Neither loss of Loxl2 nor
increased Loxl2 expression affected dermal architecture following treatment with the phor-
bol ester TPA. Furthermore, Loxl2 expression did not alter the stroma of DMBA-TPA-
induced tumours. We conclude that, although Loxl2 is expressed in both dermis and epider-
mis, its function appears largely confined to the epidermis.
Introduction
Lysyl oxidase-like 2 (LOXL2) belongs to the lysyl oxidase (LOX) protein family of copper-
dependent monoamine oxidases, which has five members, LOX and Lox-like (LOXL) LOXL1,
2, 3 and 4. These proteins are secreted into the extracellular matrix (ECM) and their expression
is tightly controlled during development [1]. Deregulated ECM remodelling occurs in patho-
logic conditions such as cancer and fibrosis [2]. Lysyl oxidases have been associated with mul-
tiple extracellular and intracellular functions affecting cell signalling, transcription and
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translation in tissue homeostasis and disease, and are currently emerging as an attractive thera-
peutic target in cancer [3]. Lysyl oxidases contribute to remodelling of the ECM by crosslink-
ing collagen and elastin through catalysis of the conversion of ε-amino groups of lysine
residues to reactive aldehydes. The latter can react either with other oxidised groups or with
lysine residues, leading to a variety of inter- and intra-chain cross-linkages. Accordingly, lysyl
oxidases are necessary for the appropriate modification of ECM components and are essential
for normal connective tissue development[2–8].
The skin is formed of two layers, the epidermis and dermis, and harbours several append-
ages, including hair follicles (HF) and sweat glands. The dermis is composed of different fibro-
blast subpopulations, which give rise to the distinct dermal sublayers: the papillary dermis
beneath the basement membrane, the collagen fibre-rich reticular dermis and the dermal
white adipose tissue (DWAT), where the pre-adipocytes and adipocytes reside. In addition,
subpopulations of fibroblasts envelope HFs (dermal sheath fibroblasts), regulate the HF cycle
(dermal papilla fibroblasts) and form the arrector pili muscle (APM) [9].
Aberrant expression of Lox family members has been associated with highly tissue specific
developmental defects in mice. Lack of the Lox gene has been shown to lead to perinatal death
caused by aortic aneurysms, cardiovascular dysfunction, and diaphragmatic rupture [10].
Loxl1 knockout (KO) mice survive the perinatal period but exhibit disturbed regeneration of
elastic fibres in the postpartum intrauterine tract and laxity of the skin, amongst other abnor-
malities associated with accumulation of the elastin precursor, tropoelastin [11]. In Loxl2 KO
mice, partial perinatal lethality is observed due to heart failure and distended hepatic capillar-
ies. However, in Loxl2 overexpressing mice only males show a phenotype, which is sterility
due to epididymal dysfunction [12]. Loss of Loxl3 has been shown to cause cleft palate and spi-
nal deformity in mice, coinciding with perinatal lethality [13].
LOXL2 has been shown to participate in ECM remodelling, and also in regulating epithe-
lial-to-mesenchymal transition, epithelial cell polarity and differentiation [14]. Moreover, in a
chemical skin carcinogenesis model, Loxl2 overexpressing mice show an increased tumour
burden, whereas Loxl2 deficient mice exhibit the opposite phenotype. LOXL2 has therefore
been identified as an attractive target for cancer treatments [12]. Mechanistically, Loxl2 nega-
tively modulates epidermal differentiation through repression of Notch1 promoter activity,
leading to a decrease in the steady state activity of the Notch1 signalling pathway. However,
the influence of Loxl2 on the dermis during development and tumour formation is unex-
plored. Therefore, in this study, we have analysed the dermis of constitutive genetic mouse
models, either lacking expression of Loxl2 or overexpressing Loxl2.
Materials and methods
Mice
All animal experiments were subject to local ethical approval, have been approved and per-
formed under the terms of a UK Government Home Office license (PPL 70/8474) and Univer-
sidad Auto´noma de Madrid (UAM) license (Re# CEI-25-587). Generation of Loxl2 knockout
(Loxl2-KO) and Loxl2 knock-in (Loxl2-KI) mice has been described previously [12].
12-O-Tetradecanoylphorbol-13-acetate (TPA) and 2,4-Dimethoxybenzaldehyde (DMBA)/
TPA-protocols were performed as described previously [12]. Briefly, TPA was applied three
times at two day intervals during one week at a dose of 12.5 μg. Loss- and gain-of-function
mice were bred on different genetic backgrounds [12], and we therefore analysed different
controls of the appropriate backgrounds. Since we did not observe any differences between the
different controls in the experiments performed, we show only one control in all figures.
PDGFRαH2BeGFP [15] mice were bred on a C57BL6/CBA background and male and female
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mice were used in experiments. Animals were sacrificed by CO2 asphyxiation or cervical dislo-
cation. All efforts were made to minimise suffering for mice.
Human tissue samples
Human foetal tissue was obtained with appropriate ethical approval from the UK Human
Developmental Biology Resource. Adult surgical waste skin from written consenting patients
under-going plastic surgery was obtained from St George’s University Hospitals NHS Founda-
tion Trust and the study was ethically approved by the National Research Ethics Service Com-
mittee UK (HTA Licence No: 12121, REC-No: 14/NS/1073). The age and anatomical location
of each tissue sample is listed in (S1 Table).
For total RNA isolation dermal cells were isolated as previously described [16]. Briefly, foe-
tal tissue was minced and digested in trypsin (0.25%) without EDTA (Invitrogen) for 1 hour at
37˚C. Human adult skin was cut into 5 mm diameter pieces and incubated with dispase for 1
hour at 37˚C; the epidermis was peeled off and discarded and the dermis was digested over-
night at 37˚C using enzymes from a whole-skin dissociation kit (Miltenyi). The resulting cell
suspensions from digested foetal and adult skin were filtered through a 70 μm cell strainer,
and centrifuged at 1500 rpm for 10 min at 4˚C. The supernatant was removed and the pellet
was washed once with PBS at 1500 rpm for 4 min at 4˚C. The pellet was resuspended in 350 μl
lysis buffer containing 2-mercaptoethanol (Qiagen) for RNA extraction.
RNA extraction and qPCR
Total RNA was isolated from FACS-sorted GFP+ fibroblasts from PDGFRαH2BeGFP mice,
isolated fibroblast subpopulations, whole-mounts of OCT-embedded skin from Loxl2-KO,
Loxl2-KI and control mice as well as from human skin using the RNeasy kit (Qiagen). Com-
plementary DNA was generated using the QuantiTect Reverse Transcription kit (Qiagen). For
the murine samples quantitative PCR (qPCR) analysis of cDNA was performed using qPCR
primers (designed with Roche Universal ProbeLibrary Assay Design Center), Roche Universal
ProbeLibrary Probes and LightCycler1 480 Probes Master (Roche). qPCR reactions were run
on a LightCycler1 480 System (Roche). Actb and 18S rRNA were used as housekeeping genes
for normalisation. Please refer to (S2 Table) for primer sequences. Expression levels between
different Lox family members can be compared, as primer efficiencies were determined previ-
ously (S2 Table).
For human samples qPCR analysis was performed on the CFX384 Real-Time System (Bio-
Rad) using SYBR-Green Master Mix (Life Technologies) and qPCR primers designed with
Primer3 (S2 Table). Values were normalised to RPL13A and TBP expression. Analysis of
mRNA expression during development (Fig 1) was performed by the delta-Ct method. Target
gene expression was normalised to housekeeping genes and the results are the calculated
2^delta-Ct values. For analysis of mRNA expression in Loxl2-KO and Loxl2-KI mice (Fig 2)
the calculated 2^delta-delta-Ct values are shown as fold change to control sample of each tar-
get gene.
Genotyping PCR
Genomic DNA from formalin-fixed, paraffin-embedded tissue sections was isolated with the
QIAamp DNA FFPE Tissue Kit (QIAGEN) following the manufacturer’s instructions. Primers
for PCR genotyping are described in (S3 Table) and have been published previously [12]. L2+
is the wild type allele, L2lox the conditional and L2- the knockout allele. R26+ is the wild type
allele in the ROSA26 locus and R26L2 the Loxl2 overexpression allele. PCR reactions were per-
formed using the MyTaq™ HS Red Mix (Bioline) and run on a 2% agarose gel.
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Flow cytometry
Fibroblasts were isolated from PDGFRαH2BeGFP mice as previously described [17–19].
Briefly, back skin of the indicated developmental time points was isolated and incubated in
dispase-trypsin solution at 37˚C for 1 hour. Neonatal dermis was separated from the epider-
mis, transferred to 0.25% collagenase in FAD medium, minced and incubated at 37˚C for 1
hour. Adult dermis was minced and incubated in FAD medium containing 1.25 mg/ml colla-
genase type I (Invitrogen), 0.5 mg/ml collagenase type II (Worthington), 0.5 mg/ml collage-
nase type IV (Sigma), 0.1 mg/ml hyaluronidase IVS (Sigma) and 50 U/ml DNase I (Sigma) at
Fig 1. Expression of Lox family members murine and human dermis. A,B: qRT-PCR analysis of Lox, Loxl1, Loxl2, Loxl3 and Loxl4 mRNA expression during mouse
development (A) and in FACS-sorted fibroblast subpopulations (papillary fibrbroblasts, CD26+ SCA1-; reticular fibroblasts, CD26- SCA1+) (B) from
PDGFRαH2BeGFP mice. C: Expression of LOX family members in human foetal and adult dermis. Details of tissue samples are shown in (S1 Table). ND = no signal
detectable.
https://doi.org/10.1371/journal.pone.0199679.g001
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Fig 2. Loxl2 ablation and overexpression are not compensated by Lox family members and do not alter dermal
histology, thickness or cell density. A: qPCR analysis of Lox family member mRNA expression in Loxl2-KO and
Loxl2 function in skin dermis
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37˚C for 1 hour. Enzyme activity was neutralised by the addition of serum-containing
medium. For cell sorting, the dermal cell suspension was passed through a 70 μm cell strainer,
washed twice with PBS and labelled with the antibodies (S4 Table) according to standard pro-
cedures. 4,6-Diamidino-2-phenylindole (DAPI) was used to exclude dead cells. Labelled cells
were sorted on a BD FACSAria Fusion gating for EGFP+ and lineage negative (CD45-, CD31-
and CD324-) cells. To obtain fibroblast subpopulations EGFP+ and lineage negative (CD45-,
CD31- and CD324-) dermal cells were further sorted into papillary (CD26+ SCA1-) and reticu-
lar (CD26- SCA1+) fibroblasts.
Histochemical stains
Skin samples were fixed in 4% PFA, embedded in paraffin and cut into 8 μm thick sections.
Before staining, sections were deparaffinised through a series of xylene (100% Xylene, 100%
Xylene; 10 minutes each) and through a series of gradient alcohols to water (100% EtOH,
100% EtOH, 95% EtOH, 95% EtOH, 70% EtOH, 70% EtOH, dH2O; 5 minutes each). Rehy-
drated sections were stained with Mayer’s Hematoxylin & Eosin (H&E), Picrosirius Red stain-
ing and Herovici staining as described below. Images were obtained with a ZEISS Axio Scan.
Z1 slide scanner. Polarised light images of Picrosirius Red stained slides were taken with a
ZEISS Axiophot equipped with a polarisation filter.
For H&E staining, slides were stained for 8 minutes in Mayer hematoxylin solution and
then washed in running tap water for 10 minutes. Sections were rinsed in distilled water, fol-
lowed by 10 rinses in 95% alcohol. Sections were counterstained in eosin Y solution for 1 min-
ute, then dehydrated through 95% alcohol and two changes of absolute alcohol (5 minutes
each). Following clearing in two changes of xylene (5 minutes each) sections were mounted in
DPX mounting medium (Sigma #06522).
Elastica van Gieson staining was performed using a kit from Merck (# 115974) according to
the manufacturer’s instructions.
Herovici’s staining solution [20] was prepared freshly with 82 ml picric acid (sat. aqu.), 8.2
ml acid fuchsin (1% aqu.), 91 ml methyl blue (0.05% aqu.), 18 ml glycerol and 900 μl Lithium
carbonate (sat. aqu.). After deparaffinisation, sections were stained using Weigert’s iron
Hematoxylin solution (Sigma) for 4 minutes to label cell nuclei. Slides were then washed for 10
minutes in running tap water and stained in Herovici’s Staining Solution for 2 minutes. After-
wards, slides were rinsed in 1% acetic acid and dehydrated and mounted as described above.
For Picrosirius Red staining, deparaffinised slides were stained with Weigert’s iron Hema-
toxylin solution as before and then stained in Picrosirius Red staining solution for 1 hour.
Afterwards, slides were washed in 0.5% acetic acid (aqu. solution) twice for 2 minutes and
dehydrated and mounted as above. When examined by polarised light microscopy, collagen
fibres appear red, green or yellow. For quantitation, a colour threshold was set in FIJI and
images were converted into a binary image.
Collagen hybridizing peptide (CHP) labelling
After deparaffinization, sections were blocked with 5% BSA/PBS for 1 hour at room tempera-
ture and stained with a biotin-conjugated collagen hybridizing peptide (B-CHP, BIO300,
3Helix) at a concentration of 5 μM overnight at 4˚C. According to the manufacturer’s
Loxl2-KI mice at P2. (n = 4 for control and Loxl2-KO; n = 2 for Loxl2-KI). B: Hematoxylin and eosin (H&E) staining.
Scale bars: 100 μm. C,D: Dermal thickness from basal membrane to hypodermis (C) and of the hypodermis (D). E,F:
Total dermal cell number in upper, papillary (E) and lower, reticular dermis (F). (n = 2 for P2 and P120 Loxl2-KI, n = 3
for all others).
https://doi.org/10.1371/journal.pone.0199679.g002
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instructions, the B-CHP probe was heated for 5 minutes at 80˚C and quenched on ice for 90
seconds, before adding it to the tissue sections. Afterwards, sections were washed three times
with PBS and incubated with Streptavidin-AlexaFluor647 (S32357, ThermoFisher Scientific)
for 1 hour at room temperature. After washing sections with PBS and incubating them with
DAPI (1 mg/ml stock solution diluted 1:10.000 in PBS) for 10 minutes at room temperature,
samples were mounted with ProLong1 Diamond Antifade Mountant (ThermoFisher Scien-
tific). Confocal microscopy was performed with a Leica TCS SP5 using a 40X objective and the
Leica LAS AF software package to stitch multiple 1024×1024 images. For CHP quantification,
mean fluorescence signal intensity was measured in the dermis and normalised to the average
fluorescence signal of 5 collagen fibres within the selected region of interest. The collagen
probe selectively intercalates in the triple helix structure of maturing, remodelling and dena-
tured collagen fibres [21,22].
Immunostaining of horizontal whole-mounts
Immunostaining was performed on 60 μm cryosections stained as horizontal whole-mounts, as
previously described [18,23]. Briefly, skin was fixed in 4% PFA for 10 minutes, washed with PBS
and embedded in OCT (Sakura Finetek). Whole-mount sections (60 μm) were cut and immedi-
ately placed in PBS to dissolve the OCT. Sections were stained in 300–500μl PB buffer (PBS con-
taining 0.5% skimmed milk, 0.25% cold water fish skin gelatin, 0.5% Triton X-100). Whole-
mounts were labelled with primary antibody overnight at 4˚C, washed in PBS for 1 hour at
room temperature, and incubated with secondary antibodies containing DAPI (1 μg/ml diluted
1:2000) for 2 hours at room temperature. Primary antibodies are listed in (S4 Table). Whole-
mounts were mounted on coverslips with glycerol and imaged with a Nikon A1 upright confo-
cal using the NIS-Elements software package to stitch multiple 1024×1024 images.
Atomic force microscopy (AFM) analysis
AFM (BioScope Resolve™ BioAFM, Bruker) synchronised with optical microscopy (Eclipse Ti-
E, Nikon) was used to assess the biomechanical properties of mouse back skin sections. Skin
samples were unfixed and cryopreserved in OCT. Prior to AFM measurement, samples were
cut to 20 μm thickness and sections were washed with PBS three times and then submerged in 1
ml of fresh PBS at room temperature. For each group, four biological replicates were analysed.
Optical microscopy was used to position the AFM cantilever tip in the dermis at a distance
of 50 μm from the epidermal-dermal junction. A silicon nitride PFQNM-LC-A-CAL AFM
probe (Bruker) was used, with a spring constant of 0.088 N/m, nominal tip radius of 70 nm,
and a semi-included tip angle of 18˚. For each replica, three force-volume (FV) measurements
were taken, with each FV data set containing 256 (= 16 x 16) measurements over a scan win-
dow of 50 μm2. Each force-separation measurement was acquired with a ramp size and rate of
6 μm and 0.5 Hz respectively and with a 2 nN trigger force. Analysis of FV data was conducted
using the Nanoscope Analysis software package (Bruker). Values of Young’s modulus were
extracted from force-separation measurements by fitting to the linearised Sneddon conical
model in the force range 0.6 to 1.4 nN with Poisson’s ratio set to 0.5. Statistical significance has
been calculated with a Tukey’s multiple comparison.
Software/ Analysis
All graphs were generated using GraphPad Prism 6 software. Data are presented as
means ± standard deviation. Unless stated otherwise, statistical significance was determined
by unpaired t-test for biological effects with an assumed normal distribution. ICY software
(version Icy 1.9.5.1) was used for image analysis and the spot-detector plugin for identification
Loxl2 function in skin dermis
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and quantification of nuclei labelled with DAPI, Ki67 or cCasp3. To quantify DLK1+, CD26+,
LRIG1+ and SCA1+ cells in the upper and lower dermis, mean fluorescence in the region of
interest was determined. Figures were prepared with Adobe Photoshop and Adobe Illustrator
(CC2017).
Results
Lox family member expression in murine and human dermis
Interrogation of published next-generation RNA sequencing data from mouse skin [24,25]
established that, while all Lox family members are predominantly expressed in dermal fibro-
blasts, dermal papillae cells and melanocytes, Loxl2 is also expressed by epithelial cells, as previ-
ously shown (Part A of S1 Fig) [12]. We confirmed expression of Lox family members by qPCR
of sorted GFP+ fibroblasts from PDGFRαH2BeGFP mice. Loxl2 mRNA was detectable from
E16.5 until P5 (Fig 1A), but not in adult fibroblasts at P21 or P50. In contrast, Lox, Loxl1 and
Loxl4 were expressed throughout development from E16.5 until P50, whereas Loxl3 expression
was detected at comparable levels to the other family members only in adult mice (Fig 1A).
When Lox family member expression is compared in papillary (CD26+ SCA1-) and reticular
(CD26- SCA1+) fibroblast subpopulations at P1, there was little difference in Loxl2, Loxl3 and
Loxl4 expression (Fig 1B). However, Lox and Loxl1 are more strongly expressed in reticular
fibroblasts which are associated with high ECM deposition and remodelling activity [16,23].
In human skin LOX family members were more strongly expressed in foetal dermis than
adult dermis, consistent with the observations in mouse dermis (Fig 1C). LOX showed the
highest expression in all samples examined.
Loxl2 loss- or gain-of-function does not affect dermal development and
homeostasis
To evaluate the impact of Loxl2 expression in dermal development and homeostasis, we ana-
lysed loss- and gain-of-function transgenic mice that have been previously generated [12]. By
qPCR and genotyping PCR, we confirmed Loxl2 loss- (Loxl2-KO) and gain-of-function
(Loxl2-KI) in the skin (Fig 2A and Part B and C of S1 Fig). We detected a pronounced increase
in Loxl2 expression in Loxl2-KI mice and down regulation in Loxl2-KO mice (Fig 2A). We did
not observe any significant change in expression of other LOX family members (Lox, Loxl1,
Loxl3 and Loxl4) in the skin of Loxl2-KO and Loxl2-KI mice (Fig 2A). When we analysed skin
from neonatal (P2) and adult mice (P21 and P120) by H&E staining, we did not observe any
differences in dermal thickness and cellularity between control, Loxl2-KO and Loxl2-KI mice
(Fig 2B–2F). In addition, macroscopic observation did not reveal any differences in HF devel-
opment, growth and cycling. When we scored cell density separately in the upper (Fig 2E) and
the lower (Fig 2F) dermis, we found that in all three genotypes the upper dermis had the high-
est cell density at P2 and that both upper and lower dermal cell density decreased with age, as
previously reported [26]. Moreover, Loxl2 gain- or loss-of-function did not affect the percent-
age of apoptotic and proliferative cells in the dermis, as measured by cleaved Caspase 3
(cCasp3) and Ki67 immunostaining, respectively, of back skin whole-mount sections (S2 Fig).
We have previously shown that at E16.5 multipotent dermal fibroblasts differentiate into
papillary, upper dermis (CD26+; LRIG1+) and reticular, lower dermis (SCA1+; DLK1+/-) fibro-
blasts [23,26]. The former give rise to cells of the papillary layer, dermal sheath, dermal papilla
and APM, the latter form the reticular dermis and further differentiate into pre- and mature
adipocytes. With age, DLK1 and LRIG1 expression are highly down regulated, whereas CD26
and SCA1 expression expand throughout the dermis. When we compared neonatal (P2) and
Loxl2 function in skin dermis
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adult (P21) skin sections of control and mutant mice, there was no obvious difference in fibro-
blast subpopulation marker expression and distribution (Fig 3A–3C and Part A and B S3 Fig).
Furthermore, the APM (highly positive for α-SMA) started to form at P2 and was fully devel-
oped at P21 in control and mutant mice (Fig 3A). Therefore, Loxl2 loss- or gain-of-function
did not influence dermal development, architecture and fibroblast subpopulation distribution.
Loxl2 overexpression affects collagen remodelling and dermal stiffness
To delineate the effect of Loxl2 loss- or gain-of-function on collagen architecture and deposi-
tion, we performed Herovici staining and Picrosirius Red staining. Throughout dermal matu-
ration from P2 to P120, the content of mature, highly-crosslinked collagen accumulated, as
shown by increased pink/purple Herovici staining in the P120 dermis (Fig 4A). Immature col-
lagen content, indicated by blue staining, was higher in P2 and P21 samples and decreased
over time (Fig 4A). In Picrosirius Red stained sections, collagen bundles appear green, red or
yellow under polarised light (Part A of S4 Fig). To quantify total collagen density, we converted
the total collagen signal into black pixels in a binary image, revealing how total dermal collagen
increased during dermal maturation, coinciding with the increasing thickness of the dermal
layer (Fig 4B and Part B of S4 Fig). Neither Herovici nor Picrosirius Red staining revealed any
significant differences between control and mutant mice.
To assess differences in collagen fibre structure, we performed staining with B-CHP, which
intercalates into accessible collagen triple helixes in maturing, remodelling and denatured col-
lagen fibres [21,22]. With age, B-CHP signal intensity increased, coinciding with increasing
thickness of the dermis and collagen maturation (Fig 4C and Part C of S4 Fig). Based on the
quantification of B-CHP, we detected a slight increase in Loxl2-KI mice; however, this was not
statistically significant (Fig 4C). To investigate whether Loxl2 gain- or loss- of function affected
dermal stiffness, we performed AFM measurements on P21 old dorsal dermis (Fig 4D and 4E).
The mean Young’s modulus E was significantly increased in Loxl2-KI and decreased in
Loxl2-KO back skin, indicating an effect of Loxl2 on skin stiffness.
In summary, although we did not observe any major differences in collagen architecture,
deposition and remodelling between controls and Loxl2 gain- or loss-of-function animals dur-
ing dermal maturation, Loxl2 did affect dermal stiffness.
Loxl2 loss- and gain-of-function do not affect the dermal TPA response
To investigate a role of Loxl2 in pathological skin conditions, we analysed the dermis of control
and mutant mice upon treatment with TPA, which is known to stimulate epidermal prolifera-
tion and skin inflammation [27,28]. After 7 days of TPA treatment we detected a comparable
increase in dermal cell density in the upper and lower dermis (Fig 5A and 5B) and a pro-
nounced epidermal hyperplasia (Fig 5C) in control and mutant mice compared to untreated
controls. To delineate the effect of Loxl2 loss- or gain-of-function on collagen architecture, we
performed Herovici and Picrosirius Red staining. In all TPA-treated skin samples, the dermis
close to the basement membrane stained slightly blue with Herovici (Fig 5D), indicating the
presence of immature and/or remodelling collagen fibres. Picrosirius Red staining revealed
high compaction of collagen fibres on TPA treatment (Fig 5E). None of the dermal effects of
TPA differed between Loxl2 mutants and control animals.
The stromal microenvironment of DMBA/TPA-induced tumours is not
altered upon Loxl2 loss- or gain-of-function
It has been shown previously that Loxl2 overexpression increases and Loxl2 loss-of-function
decreases skin tumour burden and malignant progression by affecting epidermal
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Fig 3. Fibroblast subpopulations are not affected by Loxl2 deletion or overexpression. A: Immunostaining for α-
SMA (green), DLK1 (red) and CD26 (white). B: Immunostaining for LRIG1 (red) and SCA1 (white). Nuclei are
labelled with DAPI (blue). Scale bars: 100 μm. C: Mean immunofluorescence quantification of DLK1 (left panel) and
LRIG1 (right panel) in the upper and lower dermis (n = 2 for P2 Loxl2-KI, n = 3 for all others). Data are means ±SD.
Note the high expression of DLK1 in the lower, reticular dermis and LRIG1 in the upper, papillary dermis at P2, which
are down regulated with age.
https://doi.org/10.1371/journal.pone.0199679.g003
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Fig 4. Dermal stiffness but not collagen maturation is altered in the dermis of Loxl2-depleted and overexpressing
transgenics. A: Herovici staining, enabling visualisation of immature collagen fibres (blue) and mature collagen (pink/
purple). B: Collagen density quantification of Loxl2-KO, Loxl2-KI and control skin samples at the indicated postnatal
ages. Collagen density values were calculated as collagen pixel per total tissue. C: Quantification of B-CHP signal. The
data shown are means ± SD; n = 7 (Control), n = 5 (Loxl2-KO), n = 2 (Loxl2-KI) at P21 and n = 4 (Control), n = 6
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differentiation [12]. Based on these observations, we speculated that Loxl2 might have an influ-
ence on the dermal tumour microenvironment. For this purpose, we analysed the stroma of
DMBA/TPA-induced papillomas (n = 14 control, n = 2 Loxl2-KO, n = 10 Loxl2-KI) and squa-
mous cell carcinomas (SCC) (n = 4 control, n = 2 Loxl2-KO, n = 1 Loxl2-KI) by H&E, Herovici
and Picrosirius Red staining (Fig 6A–6C). The grade of differentiation of the tumours was
comparable, regardless of genotype. There was no obvious difference in labelling for α-smooth
muscle actin (α-SMA), a reported marker of cancer associated fibroblasts, or cell density in the
stroma of papillomas from mice of different genotypes (Fig 6D and 6E).
While the stromal labelling differed to some extent between tumours and in different
regions of the same tumour, we saw no consistent effects of Loxl2 expression. In SCCs, we
found prominent transepidermal elimination (perforation) of collagen fibres to a comparable
extent in all genotypes (Fig 6F). Transepidermal elimination of collagen fibres was not
observed in papillomas. Accordingly, we found no evidence that Loxl2 expression affected the
stroma of DMBA/TPA-induced tumours.
Discussion
ECM assembly during dermal maturation involves crosslinking between collagen fibres to sta-
bilise collagen microfibril structure [29]. How different Lox family members are involved in
this process and influence skin dermal structure and mechanical properties is still poorly
explored. Deregulated expression of LOXL2 has been implicated in the development of fibrosis
and cancer in a variety of tissues and organs [3,14,30,31]. In human lung and liver fibrosis,
LOXL2 is overexpressed and treatments with an inhibitory monoclonal antibody against
LOXL2 were reported to be beneficial [32]. However, further studies in a large cohort of idio-
pathic lung fibrosis did not show a clinical benefit [33]. In light of divergent evidence on the
therapeutic potential of targeting stromal LOXL2, it is important to elucidate the effect of
LOXL2 modulation on tissue development and homeostasis.
In this study, we have examined the effect of Loxl2 gain- or loss-of-function in the dermis.
Surprisingly, while aberrant Loxl2 expression severely affects the heart and testis [12], neither
Loxl2 loss- nor gain-of function influenced dermal development and cell density. In addition,
there was no effect on the distribution of fibroblast subpopulations, fibroblast proliferation or
apoptosis. There was no significant up- or down-regulation of other Lox family members, sug-
gesting that no significant compensatory mechanisms were required for normal dermal matu-
ration and homeostasis on mRNA level. In Loxl2-KI transgenics we could observe a slight
increase in collagen remodelling activity with age. Loxl2 expression did, however, influence
dermis stiffness in adult mice.
The dermal changes induced by TPA occurred independently of genotype. This shows that
LOXL2 is dispensable for TPA-induced epidermal hyperproliferation and skin inflammation.
Thus, while in lung and liver LOXL2 has been identified as central regulator of tissue stiffness
[34], this would appear not to be the case in skin. This would explain why LOXL2 inhibition as
a treatment for fibrosis is not reported to affect the skin.
There was no effect of Loxl2 expression on the stroma of DMBA/TPA-induced papillomas
and SCCs. We speculate that the increased skin tumour burden in Loxl2 gain-of-function mice
is induced by LOXL2’s intracellular epidermal functions, such as inhibition of terminal
(Loxl2-KO), n = 2 (Loxl2-KI) at P120. ns; not significant. D,E: AFM measurments of P21 old dorsal dermis.
Experimental strategy with a representative 50 μm2 scan area showing the Young’s Modulus E distribution (D).
Quantification of Young’s modulus E distribution in control, Loxl2-KO and Loxl2-KI dermis at P21. The mean is
shown below (n = 4 biological replicates per genotype with 3 scan areas per sample).
https://doi.org/10.1371/journal.pone.0199679.g004
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Fig 5. Loxl2 deletion or overexpression do not affect skin response to TPA. A,B: Quantification of dermal cells in the upper,
papillary (A) and lower, reticular (B) dermis upon TPA treatment. The data shown are means ± SD; n = 2 (untreated control), n = 6
(Control TPA), n = 2 (Loxl2-KO TPA), n = 3 (Loxl2-KI TPA). C: Hematoxylin and eosin (H&E) staining. D: Herovici staining. E:
Picrosirius red staining visualised in polarised light. Scale bars: 100 μm.
https://doi.org/10.1371/journal.pone.0199679.g005
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Fig 6. Loxl2 overexpression or deletion does not influence the tumour stroma composition of DMBA/TPA-
induced papilloma. A-C: Hematoxylin and eosin (H&E) staining (A), Herovici staining (B), Picrosirius red staining
(C) of DMBA/TPA induced papillomas from Loxl2-KO, Loxl2-KI and control mice. D: Immunostaining for α-SMA
(green) in papillomas from Loxl2-KO, Loxl2-KI and control mice. Nuclei are labelled with DAPI (blue). E:
Quantification of tumour stroma cell density. The data shown are means ± SD; (n = 3 control, n = 2 Loxl2-KO, n = 2
Loxl2-KI). F: Transepidermal perforation in an SCC stained with Elastica van Gieson Staining. Representative image
for all genotypes is shown. Scale bars: 100 μm.
https://doi.org/10.1371/journal.pone.0199679.g006
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differentiation, promoting epithelial-mesenchymal transition or altering epithelial cell polarity
(14). Similarly, it has been shown recently that in breast cancer the pro-metastatic function of
LOXL2 is independent of its role for ECM remodelling, since neither Loxl2 ablation nor over-
expression affected ECM stiffness or organisation in the metastatic and primary tumour sites
[35]. In contrast, increased LOX secretion in the same tumour type drives matrix stiffening
through collagen crosslinking, hereby enabling tumour cell dissemination and metastasis [36].
These observations underline the complex and paradoxical role of Lox family members in vari-
ous types of cancer [31,37,38].
It has been shown recently that Lox family members are differentially expressed during
wound healing in murine myofibroblasts. While Loxl2 and Loxl3 are significantly up regulated,
expression of Loxl4 is decreased, suggesting that different crosslinking enzymes are needed to
stabilise the granulation tissue in a wound [39]. However, wound healing is not affected in the
different Loxl2 mice genotypes (F Salvador, A Martin & A Cano, unpublished observation),
suggesting that LOXL2 is dispensable.
In summary, we have shown that Loxl2 expression is not essential for dermal development,
homeostasis or tumour stroma formation. Our study emphasises the need to further dissect
the functions of LOX family members in order to develop successful LOX targeted treatment
strategies for fibrosis and cancer [31].
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Loxl2-KO (detected allele L2-) (B) and Loxl2-KI (detected allele R26L2) (C) mice and the corre-
sponding controls (detected allele L2lox and R26+). N = 2 biological replicates are shown.
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S2 Fig. Dermal proliferation and apoptosis are unaffected by Loxl2 deletion or overexpres-
sion. A: Cleaved caspase 3 (cCasp3) staining (red); B: Ki67 staining (red). Immunostaining for
Itga6 (green) labels the basement membrane and nuclei are labelled with DAPI (blue). Scale
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in the dermis. Single data points for each mouse are shown and plotted with the mean; n = 2
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(n = 2 for P2 Loxl2-KI, n = 3 for all others). Data are shown as means ±SD.
(TIF)
S4 Fig. Collagen fibres in the extracellular matrix of Loxl2-KO and Loxl2-KI mice dermis
are not changed upon deletion or overexpression of Loxl2. A,B: Picrosirius red staining of
Loxl2-KO, Loxl2-KI and control skin samples at P2, P21 and P120 visualised in polarised light
(A) and shown in binary images (B). C: Collagen fibre structure in the dermis was analysed by
B-CHP-staining (green); sections were counterstained with DAPI (blue). Scale bars: 100 μm.
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